Asset Details
Do you wish to reserve the book?
Immunohistochemical validation of COL3A1, GPR158 and PITHD1 as prognostic biomarkers in early-stage ovarian carcinomas
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Immunohistochemical validation of COL3A1, GPR158 and PITHD1 as prognostic biomarkers in early-stage ovarian carcinomas
Do you wish to request the book?
Immunohistochemical validation of COL3A1, GPR158 and PITHD1 as prognostic biomarkers in early-stage ovarian carcinomas
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Immunohistochemical validation of COL3A1, GPR158 and PITHD1 as prognostic biomarkers in early-stage ovarian carcinomas
2019
Overview
Background
Ovarian cancer is the main cause of gynecological cancer-associated death. However, 5-year survival rates differ dramatically between the five main ovarian carcinoma histotypes. Therefore, we need to have a better understanding of the mechanisms that promote histotype-specific ovarian carcinogenesis and identify novel prognostic biomarkers.
Methods
Here, we evaluated the prognostic role of 29 genes for early-stage (I and II) ovarian carcinomas (
n
= 206) using immunohistochemistry (IHC).
Results
We provide evidence of aberrant protein expression patterns for Collagen type III alpha 1 chain (COL3A1), G protein-coupled receptor 158 (GPR158) and PITH domain containing 1 (PITHD1). Kaplan-Meier survival analysis revealed that COL3A1 expression was associated with shorter overall survival in the four major histotypes of epithelial ovarian carcinoma patients (
P
value = 0.026, HR = 2.99 (95% CI 1.089–8.19)). Furthermore, GPR158 and PITHD1 were shown to be histotype-specific prognostic biomarkers, with elevated GPR158 expression patterns in mucinous ovarian carcinoma patients with unfavorable overall survival (
P
value = 0.00043, HR = 6.13 (95% CI 1.98–18.98)), and an association with lower PITHD1 protein expression and unfavorable overall and disease-specific survival in clear-cell ovarian carcinoma patients (
P
value = 0.012, HR = 0.22 (95% CI 0.058–0.80);
P
value = 0.003, HR = 0.17 (95% CI 0.043–0.64)).
Conclusions
The novel biomarkers identified here may improve prognostication at the time of diagnosis and may assist in the development of future individualized therapeutic strategies for ovarian carcinoma patients.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
Adenocarcinoma, Clear Cell - metabolism
/ Adenocarcinoma, Clear Cell - pathology
/ Adenocarcinoma, Mucinous - metabolism
/ Adenocarcinoma, Mucinous - pathology
/ Adult
/ Aged
/ Antigens
/ Biomarkers, Tumor - metabolism
/ Biomedical and Life Sciences
/ Collagen
/ Collagen Type III - metabolism
/ Death
/ Female
/ Genes
/ Health Promotion and Disease Prevention
/ Humans
/ Novels
/ Oncology
/ Ovarian Neoplasms - metabolism
/ Ovarian Neoplasms - mortality
/ Ovarian Neoplasms - pathology
/ Patients
/ Proteins
